truncated AUC [NCA / SHAM]

posted by drcampos  – Brazil, 2007-07-25 19:21 (6491 d 17:16 ago) – Posting: # 940
Views: 5,346

Dear Helmut,

Articles and Guidances have said that the use of truncated area under the curve could be a significant advantage for BE studies of drugs with long half-lives and low intrasubject variability. So, I would like to know why is not truncated AUC a good option to high intrasubject variability drug?

Regards,

Daniel Rossi de Campos
Brazil

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,671 registered users;
200 visitors (0 registered, 200 guests [including 8 identified bots]).
Forum time: 12:38 CEST (Europe/Vienna)

If you tell the truth you don’t have to remember anything.    Mark Twain

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5